Akademik Veri Yönetim Sistemi
Northern Clinics of Istanbul, cilt.12, sa.5, ss.597-603, 2025 (ESCI, Scopus, TRDizin)
OBJECTIVE: This study was designed to evaluate the relationship between Atherogenic Plasma Index (API), a cardiovascular event risk marker, and hepatic fibrosis level in non-alcoholic fatty liver disease (NAFLD) patients. METHODS: 129 people over the age of 18 with NAFLD were included in the study. Fasting blood glucose (FBG), HOMA-IR, HbA1C, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), albumin, triglyceride (TG), total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), nonHDL-cholesterol (nonHDL-C), direct bilirubin, TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios were calculated. NAFLD fibrosis score (NFS), FIB-4, APRI scores were determinated. It was classified as low, high and intermediate. The API was calculated and its relationship with the level of hepatic fibrosis was evaluated. RESULTS: The API level in the high group of NFS is higher than that in the low group. Similarly, the API level in the high group of FIB-4 is higher than that in the low group. The API in the low group of APRI are lower than the ID group. There is a positive correlation between API and NFS, FIB-4, APRI scores in all NAFLD subjects. There is a positive correlation between API and NFS, FIB-4, APRI scores in all NAFLD subjects in the study. CONCLUSION: In this study, we found that there was a relationship between FIB-4, NFS, APRI scores, API and dyslipidemia in people with NAFLD, and that as the level of fibrosis increased, the risk of cardiovascular event also increased. Liver fibrosis scores can also be used as cardiovascular risk markers.